I-Mab has begun the new year with a pipeline pivot, pausing work on an asset that Sanofi bought into last year to focus on ...

British tech firm Basecamp Research is making a big push forward to further its mission of developing programmable genetic ...

Xeno Biosciences may have been unable to prove that its drug delivering oxygen to the gastrointestinal tract can induce ...

Oculis’ peptidomimetic small molecule has been shown to help protect the eyes of patients with inflammation of the optic ...

As a global life sciences company, Astellas is passionate about partnering to advance life-changing treatments for patients. | Discover how Astellas builds innovation partnerships with ambitious organ ...

Overall, biopharma layoffs rose ever so slightly in 2024 compared to the year before, though the number of layoff rounds ...

San Diego-based iBio has signed a backloaded agreement with its existing partner AstralBio for a preclinical anti-myostatin ...

In September of last year, the FDA said it had begun exploring the potential health effects of various metals that have been ...

Last December, the FDA published its final guidance on predetermined change control plans, or PCCPs, with recommendations to ...

Regeneron has scooped up Oxular, a retinal-disease-focused company based in the U.K., closing the deal at the very end of ...

Now, China-based CARsgen has shared pivotal results from the latter portion of a phase 1/2 study evaluating the therapy for ...

Will 2025 be better? After another tough year, the answer to that question will shape the prospects of innumerable drug ...